Company profile
GB Sciences, Inc.
OTC: GBLX · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ 37GM —SS 33
v0.1 · 25/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ workforce scale, Altman-Z
Methodology →Revenue TTM
$97.2k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.4M
Employees
2
as of 2026-08-28
Market cap
$122.1k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$1.4M-$1.4M2024
Operating income-$1.4M-$1.4M2024
Total assets$103.4k$103.4k2024
Liabilities$5.4M$5.4M2024
Equity-$5.3M-$5.3M2024
Revenue trend
FY2017 – FY2024 · USD
FY17
FY18
FY19
FY20
FY22
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is GB Sciences, Inc.’s revenue?
GB Sciences, Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
TripSitter Clinic Ltd.——Indigenous Bloom Hemp Corp.——DrazCanna, Inc.——Manzo Pharmaceuticals, Inc.57CImmunotech Laboratories, Inc.——Link Reservations Inc.——Neighbors
Clark →Key facts
CEOAndrea Small-Howard
SectorHealthcare
IndustryBiotechnology
HeadquartersLas Vegas, NV
ExchangeOTC: GBLX
Employees2
IPO date2008-05-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.